Trial · NCT01857063
Results by group72
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 72
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Total Nasal Symptom Score (TNSS) Averaged During 3 Hours of Exposure | Montelukast | 1.17 | 95% Confidence Interval 1.03 to 1.31 | score on a scale | |
| Change From Baseline in Total Nasal Symptom Score (TNSS) Averaged During 3 Hours of Exposure | Placebo | 1.18 | 95% Confidence Interval 1.04 to 1.32 | score on a scale | |
| Percentage of Participants Who Experience at Least One Adverse Event | Montelukast | 10.2 | percentage of participants | ||
| Percentage of Participants Who Experience at Least One Adverse Event | Placebo | 16.5 | percentage of participants | ||
| Change From Baseline in Weighted TNSS Averaged During 3 Hours of Exposure | Montelukast | 1.85 | 95% Confidence Interval 1.63 to 2.07 | score on a scale | |
| Change From Baseline in Weighted TNSS Averaged During 3 Hours of Exposure | Placebo | 1.86 | 95% Confidence Interval 1.63 to 2.08 | score on a scale | |
| Change From Baseline in Nasal Congestion Score Averaged During 3 Hours of Exposure | Montelukast | 0.68 | 95% Confidence Interval 0.59 to 0.76 | score on a scale | |
| Change From Baseline in Nasal Congestion Score Averaged During 3 Hours of Exposure | Placebo | 0.68 | 95% Confidence Interval 0.59 to 0.76 | score on a scale | |
| Change From Baseline in Nasal Discharge Score Averaged During 3 Hours of Exposure | Montelukast | 0.29 | 95% Confidence Interval 0.25 to 0.34 | score on a scale | |
| Change From Baseline in Nasal Discharge Score Averaged During 3 Hours of Exposure | Placebo | 0.32 | 95% Confidence Interval 0.27 to 0.37 | score on a scale | |
| Change From Baseline in Sneezing Score Averaged During 3 Hours of Exposure | Montelukast | 0.20 | 95% Confidence Interval 0.16 to 0.24 | score on a scale | |
| Change From Baseline in Sneezing Score Averaged During 3 Hours of Exposure | Placebo | 0.18 | 95% Confidence Interval 0.14 to 0.22 | score on a scale | |
| Change From Baseline in TNSS at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Montelukast | 30 minutes after entering chamber room | 0.54 | 95% Confidence Interval 0.42 to 0.67 | score on a scale |
| Change From Baseline in TNSS at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Placebo | 30 minutes after entering chamber room | 0.59 | 95% Confidence Interval 0.46 to 0.71 | score on a scale |
| Change From Baseline in TNSS at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Montelukast | 60 minutes after entering chamber room | 1.00 | 95% Confidence Interval 0.84 to 1.16 | score on a scale |
| Change From Baseline in TNSS at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Placebo | 60 minutes after entering chamber room | 1.07 | 95% Confidence Interval 0.91 to 1.23 | score on a scale |
| Change From Baseline in TNSS at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Montelukast | 90 minutes after entering chamber room | 1.36 | 95% Confidence Interval 1.18 to 1.55 | score on a scale |
| Change From Baseline in TNSS at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Placebo | 90 minutes after entering chamber room | 1.31 | 95% Confidence Interval 1.12 to 1.49 | score on a scale |
| Change From Baseline in TNSS at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Montelukast | 120 minutes after entering chamber room | 1.38 | 95% Confidence Interval 1.18 to 1.57 | score on a scale |
| Change From Baseline in TNSS at 30, 60, 90, 120, 150 and 180 Minutes After Entering Chamber Room | Placebo | 120 minutes after entering chamber room | 1.35 | 95% Confidence Interval 1.16 to 1.54 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01857063/results